favld
Vaccineexperimental
Favus or tinea favosa is the severe form of tinea capitis, a skin infectious disease caused by the dermatophyte fungus Trichophyton schoenleinii. Typically the species affects the scalp, but occasionally occurs as onychomycosis, tinea barbae, or tinea corporis. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00036426)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Unknown
- Tumor antigensImmunity, active
Tumor antigens immunity, active
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFavus ↗
- ChEMBLCHEMBL2109085 ↗
Also known as
- detumomab
- favid
- favid
- favid
- specifid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00324831 | Phase 3 | May 10, 2006 | Favrille |
| NCT00036426 | Phase 2 | Mar 1, 2001 | Favrille |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Favrille | For profit | 2 | 2 | 2 | 2001 |
1 organizations
Page 1 / 1